A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS

Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zafar, Aneeqa Ahsan, Kouides, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141713/
https://www.ncbi.nlm.nih.gov/pubmed/32274030
http://dx.doi.org/10.1002/ccr3.2728
_version_ 1783519249762877440
author Zafar, Aneeqa Ahsan
Kouides, Peter
author_facet Zafar, Aneeqa Ahsan
Kouides, Peter
author_sort Zafar, Aneeqa Ahsan
collection PubMed
description Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascular risk factors might be beneficial in preventing future cardiovascular mortality.
format Online
Article
Text
id pubmed-7141713
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71417132020-04-09 A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS Zafar, Aneeqa Ahsan Kouides, Peter Clin Case Rep Case Reports Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascular risk factors might be beneficial in preventing future cardiovascular mortality. John Wiley and Sons Inc. 2020-02-18 /pmc/articles/PMC7141713/ /pubmed/32274030 http://dx.doi.org/10.1002/ccr3.2728 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Zafar, Aneeqa Ahsan
Kouides, Peter
A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_full A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_fullStr A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_full_unstemmed A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_short A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_sort presumed case of darbepoetin‐induced myocardial infarction in the patient with mds‐rars
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141713/
https://www.ncbi.nlm.nih.gov/pubmed/32274030
http://dx.doi.org/10.1002/ccr3.2728
work_keys_str_mv AT zafaraneeqaahsan apresumedcaseofdarbepoetininducedmyocardialinfarctioninthepatientwithmdsrars
AT kouidespeter apresumedcaseofdarbepoetininducedmyocardialinfarctioninthepatientwithmdsrars
AT zafaraneeqaahsan presumedcaseofdarbepoetininducedmyocardialinfarctioninthepatientwithmdsrars
AT kouidespeter presumedcaseofdarbepoetininducedmyocardialinfarctioninthepatientwithmdsrars

Ejemplares similares